Brookline Capital Management Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Brookline Capital Management
Rating: 2.6
Author: MarketBeat

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

Brokerage Ranking: Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Total Ratings: 30 Last 12 Months
Buy Ratings: 22 Last 12 Months
Sell Ratings: 0 Last 12 Months
Companies Covered: 23 Last 12 Months

Company	Current Price	Report Date	Analyst	Action	Price Target	Rating	Details
IMAB I-Mab	$4.09 +4.9%	8/28/2025		Reiterated Rating		Buy	View details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 8/28/2025
BIOX Bioceres Crop Solutions	$2.04 -2.4%	8/21/2025		Downgrade		Strong-Buy ➝ Hold	View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 8/21/2025
RNTX Rein Therapeutics	$1.19 +10.2%	8/19/2025	Kemp Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for Brookline Capital Management rating of Rein Therapeutics (NASDAQ:RNTX) on 8/19/2025
ICCM IceCure Medical	$0.99 -0.8%	8/13/2025		Reiterated Rating		Buy	View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 8/13/2025
YMAB Y-mAbs Therapeutics	$8.59	8/5/2025		Downgrade		Strong-Buy ➝ Hold	View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 8/5/2025
RADX Radiopharm Theranostics	$6.50 +4.0%	7/21/2025	Kemp Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$18.00	Buy	View details for Brookline Capital Management rating of Radiopharm Theranostics (NASDAQ:RADX) on 7/21/2025
LSTA Lisata Therapeutics	$2.19 -2.2%	7/15/2025	Kemp Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Price Target	$20.00 ➝ $32.00	Buy	View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 7/15/2025
CADL Candel Therapeutics	$4.79 -2.4%	7/9/2025	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of Candel Therapeutics (NASDAQ:CADL) on 7/9/2025
HURA TuHURA Biosciences	$2.50 -3.5%	6/23/2025	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of TuHURA Biosciences (NASDAQ:HURA) on 6/23/2025
BIVI BioVie	$1.87 -0.5%	3/18/2025	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of BioVie (NASDAQ:BIVI) on 3/18/2025
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
CRVO CervoMed	$8.85 -3.8%	3/11/2025	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Hold ➝ Strong-Buy	View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 3/11/2025
CATX Perspective Therapeutics	$3.48 +3.0%	3/10/2025	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of Perspective Therapeutics (NYSE:CATX) on 3/10/2025
IMAB I-Mab	$4.09 +4.9%	2/27/2025	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 2/27/2025
MRKR Marker Therapeutics	$0.95 -1.6%	2/10/2025	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of Marker Therapeutics (NASDAQ:MRKR) on 2/10/2025
CGTX Cognition Therapeutics	$2.17 -8.1%	1/27/2025	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of Cognition Therapeutics (NASDAQ:CGTX) on 1/27/2025
MDCX Medicus Pharma	$2.41 +7.1%	12/23/2024	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of Medicus Pharma (NASDAQ:MDCX) on 12/23/2024
EXEL Exelixis	$39.15 +0.2%	12/23/2024	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage		Buy	View details for Brookline Capital Management rating of Exelixis (NASDAQ:EXEL) on 12/23/2024
QNCX Quince Therapeutics	$1.60 +1.3%	12/18/2024	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$9.00	Buy	View details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024
CRVO CervoMed	$8.85 -3.8%	12/10/2024	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Strong-Buy ➝ Hold	View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024
YMAB Y-mAbs Therapeutics	$8.59	12/4/2024	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024
YMAB Y-mAbs Therapeutics	$8.59	12/5/2024		Initiated Coverage	$17.00	Buy	View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024
HYPD Hyperion DeFi	$14.98 +24.9%	11/15/2024	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy ➝ Hold	View details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 11/15/2024
COCH Envoy Medical	$1.29 -3.0%	10/14/2024	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$9.00	Buy	View details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024
VRCA Verrica Pharmaceuticals	$4.75 -3.8%	10/2/2024	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy ➝ Hold	View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024
OSTX OS Therapies	$2.25 -2.6%	8/22/2024	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024
MEIP MEI Pharma	$3.19 +14.7%	7/22/2024	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Strong-Buy ➝ Hold	View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 7/22/2024
IBIO iBio	$0.93 -3.1%	7/22/2024	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$3.60	Buy	View details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024
UNCY Unicycive Therapeutics	$3.87 -5.4%	7/9/2024	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024
CRVO CervoMed	$8.85 -3.8%	7/8/2024	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$63.00	Buy	View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024
SABS SAB Biotherapeutics	$2.12	6/7/2024		Initiated Coverage	$8.00	Buy	View details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024
FBRX Forte Biosciences	$10.56 +1.0%	5/30/2024		Initiated Coverage	$4.00	Buy	View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024
DARE Dare Bioscience	$2.11	5/15/2024	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	$36.00	Hold ➝ Buy	View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 5/15/2024
DARE Dare Bioscience	$2.11	4/17/2024	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/17/2024
IMUX Immunic	$0.79 -6.8%	4/5/2024	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$10.00	Buy	View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024
ANVS Annovis Bio	$2.49 +4.2%	2/28/2024	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	$9.00	Buy ➝ Hold	View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024
OTLK Oncobiologics	$1.04 -4.6%	1/25/2024	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	$31.40	Hold ➝ Buy	View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 1/25/2024
CYCC Cyclacel Pharmaceuticals	$6.44 -4.9%	12/19/2023	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 12/19/2023
LNTH Lantheus	$52.94 -3.7%	11/30/2023		Initiated Coverage	$100.00	Buy	View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023
ANVS Annovis Bio	$2.49 +4.2%	11/10/2023	T. Bussian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$35.00	Buy	View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023
GNLX Genelux	$3.95 +8.2%	10/30/2023	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Hold ➝ Buy	View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023

HYPD Hyperion DeFi	$14.98 +24.9%	10/17/2023		Initiated Coverage	$640.00	Buy	View details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 10/17/2023
EDSA Edesa Biotech	$2.45 +1.6%	10/12/2023		Reiterated Rating	$57.00	Buy	View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023
OTLK Oncobiologics	$1.04 -4.6%	8/30/2023	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 8/30/2023
DARE Dare Bioscience	$2.11	2/14/2023	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 2/14/2023
ECOR electroCore	$4.74 -5.6%	1/12/2023	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023
IMNN Imunon	$5.75 +1.8%	11/14/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022
VXRT Vaxart	$0.39 +0.0%	10/3/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022
OTLK Oncobiologics	$1.04 -4.6%	10/3/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 10/3/2022
MNPR Monopar Therapeutics	$49.22 +3.3%	10/3/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022
LSTA Lisata Therapeutics	$2.19 -2.2%	10/3/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022
IMNN Imunon	$5.75 +1.8%	10/3/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022
EDSA Edesa Biotech	$2.45 +1.6%	10/3/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022
CYCC Cyclacel Pharmaceuticals	$6.44 -4.9%	10/3/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 10/3/2022
ARCT Arcturus Therapeutics	$17.32 -4.0%	8/10/2022	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022
VERU Veru	$3.45 -3.1%	5/18/2022	Kumaraguru Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Price Target	$290.00 ➝ $310.00	Buy	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022
VRCA Verrica Pharmaceuticals	$4.75 -3.8%	3/10/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022
NTLA Intellia Therapeutics	$11.42	3/7/2022	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	$91.00	Hold ➝ Buy	View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022
CRSP CRISPR Therapeutics	$56.26 +0.7%	2/14/2022	Leah Rush Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$143.00	Buy	View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022
NTLA Intellia Therapeutics	$11.42	2/14/2022	Leah Rush Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022
CRBU Caribou Biosciences	$1.80 -5.8%	2/14/2022	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022
BCDA BioCardia	$2.14 -5.7%	2/3/2022	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022
ICCM IceCure Medical	$0.99 -0.8%	2/1/2022	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022
DARE Dare Bioscience	$2.11	1/19/2022	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 1/19/2022
KYMR Kymera Therapeutics	$46.99 +1.7%	10/13/2021	Leah Rush Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$80.00	Buy	View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021
FBRX Forte Biosciences	$10.56 +1.0%	9/3/2021	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Hold	View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021
VERU Veru	$3.45 -3.1%	8/27/2021	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021
SCYX SCYNEXIS	$1.12 -5.1%	8/24/2021	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021
CCCC C4 Therapeutics	$2.66 -2.6%	6/25/2021	Leah Rush Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021
MNPR Monopar Therapeutics	$49.22 +3.3%	5/25/2021	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021
BIOX Bioceres Crop Solutions	$2.04 -2.4%	5/7/2021	K. Dolliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021
MRNA Moderna	$23.51 -7.4%	2/26/2021		Boost Price Target	$180.00 ➝ $205.00	Buy	View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021
XFOR X4 Pharmaceuticals	$3.26 -1.2%	12/17/2020	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$630.00	Buy	View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020
VERU Veru	$3.45 -3.1%	12/14/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Price Target	$130.00 ➝ $170.00		View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020
ECOR electroCore	$4.74 -5.6%	10/23/2020	S. Yanchus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$75.00	Buy	View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020
MEIP MEI Pharma	$3.19 +14.7%	10/12/2020	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020
FBRX Forte Biosciences	$10.56 +1.0%	8/28/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$90.00	Buy	View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020
KURA Kura Oncology	$8.19 -7.1%	8/16/2020	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020
VERU Veru	$3.45 -3.1%	8/14/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020
ARCT Arcturus Therapeutics	$17.32 -4.0%	8/11/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020
MRNA Moderna	$23.51 -7.4%	7/13/2020	L. Cann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$95.00	Buy	View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020
ASRT Assertio	$0.81 +1.0%	6/3/2020		Initiated Coverage	$3.50	Buy	View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020
CYCC Cyclacel Pharmaceuticals	$6.44 -4.9%	5/19/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$79,200.00	Buy	View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 5/19/2020
OTLK Oncobiologics	$1.04 -4.6%	5/5/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage		Buy	View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 5/5/2020
DARE Dare Bioscience	$2.11	4/28/2020	S. Yanchus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$90.00	Buy	View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/28/2020
EDSA Edesa Biotech	$2.45 +1.6%	3/30/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$70.00	Buy	View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020
CLPT ClearPoint Neuro	$10.49 -5.4%	3/11/2020	S. Yanchus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020
CLPT ClearPoint Neuro	$10.49 -5.4%	3/12/2020		Initiated Coverage	$15.00	Buy	View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020
MNPR Monopar Therapeutics	$49.22 +3.3%	2/19/2020	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$210.00	Buy	View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020
BIOX Bioceres Crop Solutions	$2.04 -2.4%	2/4/2020	S. Yanchus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020
BCDA BioCardia	$2.14 -5.7%	11/26/2019	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019

BCDA BioCardia	$2.14 -5.7%	11/26/2019		Initiated Coverage	$330.00	Buy	View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019
SCYX SCYNEXIS	$1.12 -5.1%	8/19/2019	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019
VXRT Vaxart	$0.39 +0.0%	8/15/2019	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$6.00	Buy	View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019
VERU Veru	$3.45 -3.1%	7/29/2019	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$120.00	Buy	View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019
CLRB Cellectar Biosciences	$5.08 -3.8%	7/29/2019	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$1,800.00 ➝ $1,800.00	Buy	View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019
ARCT Arcturus Therapeutics	$17.32 -4.0%	7/24/2019	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019
SCYX SCYNEXIS	$1.12 -5.1%	1/4/2019	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019
CLRB Cellectar Biosciences	$5.08 -3.8%	11/20/2018	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018
ARCT Arcturus Therapeutics	$17.32 -4.0%	9/27/2018	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018
TNXP Tonix Pharmaceuticals	$28.61 -8.3%	7/27/2018	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Buy ➝ Hold	View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018
TNXP Tonix Pharmaceuticals	$28.61 -8.3%	5/1/2018	K. Raja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:		2.6 out of 5 ( 2.6 of 5 stars)
Outperform Votes:		52,704 (Thanks for Voting!)
Underperform Votes:		48,291 (Thanks for Voting!)
Total Votes:		100,995

MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brookline Capital Management Analyst Recommendations & Stock Picks

MarketBeat Community Rating for Brookline Capital Management

Stock Forecasts and Research Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brookline Capital Management Analyst Recommendations & Stock Picks

MarketBeat Community Rating for Brookline Capital Management

Stock Forecasts and Research Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools